Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS). Early-stage studies have explored safety, tolerability, and preliminary signals of biological activity, while ongoing Phase 2 trials aim to evaluate efficacy endpoints in patient populations. The company has also initiated trials in spinal cord injury to investigate broader applications of its nanoparticle technology in central nervous system repair and protection.
Headquartered in Salt Lake City, Utah, Clene maintains research and development operations in the United States and collaborates with academic institutions and clinical sites across North America and Australia. These partnerships support its translational research efforts and enable access to patient cohorts for clinical investigation. Clene has secured manufacturing capabilities for its nanoparticle formulations and is working to scale production processes in anticipation of later-stage clinical studies and potential commercialization.
Clene is led by a management team with experience in biotechnology development, neuroscience research, and clinical operations. The company continues to expand its leadership bench through strategic hires and external collaborations, with the goal of advancing its pipeline of nanoparticle therapeutics toward regulatory approval and broader patient access.
AI Generated. May Contain Errors.
